HIV NOTES.presentation notes quick understanding pdf

Quick academic notes

1. 1
INFECTIOUS DISEASES
HIV Infection
HIV NOTES 1

2. HIV Infection
•HIV causes acquired immunodeficiency syndrome(AIDS).
•Clinical manifestations of AIDS result from consequences
of a critically impaired immune system.
•Almost 90% of deaths are caused by opportunistic infectio
ns.
Pathogenesis
•HIV isretrovirus(family -retroviridae; subfamily -lentivirus
).
•RNA virus which has enzymereverse transcriptase and c
onsists of a lipid bilayer membrane surrounding the capsid.
•surface glycoprotein molecule(gp120) has strong affinity f
or CD4 receptor protein on T –helper/inducer lymphocytes.
•Monocytes and macrophages also express CD4 receptor.
SiulapwaRodney 2HIV NOTES 2

3. Siulapwa Rodney 3HIV NOTES 3

4. •HIV entry is a complex multistage process involving CD4 at
tachment, binding to chemokine co –receptors such as CC
R -5 and CXCR -4, and membrane fusion.
•After penetrating the host cell, the virus sheds its outer coat
and releases its genetic material (RNA).
•Viral RNA is converted to viral DNA using nucleosides, by r
everse transcriptase.
•Viral DNA is integrated(inserted) into the host genome(DN
A) by the enzymeintegrase.
•Viral DNA undergoes transcriptionand translation, producin
g new viral proteins.
•New virus particles are assembled and bud out of the host
cell.
•Maturation of new virus particles into infectious virions requ
ire the action of protease enzyme.
•Protease cleaves the precursor proteins into functional poly
peptides.
Siulapwa Rodney 4HIV NOTES 4

5. Siulapwa Rodney 5HIV NOTES 5

6. Siulapwa Rodney 6HIV NOTES 6

7. Clinical Manifestations
•Sequelae of untreated HIV infection divided into five group
s:
1.Opportunistic infections (infections that do not normally c
ause disease in immunocompetent hosts) e.g. P. jiroveci p
neumonia, CMV retinitis
2.Infections that can occur in immunocompetent patients b
ut are more frequent, more severe and more atypical in HIV
patients e.g. Salmonella, herpes simplex and Mycobacteriu
m tuberculosis
3.Malignancies that occur rarely in immunocompetent patie
nts e.g. Kaposi’s sarcoma, non –Hodgkin’s lymphoma.
4.Direct manifestations of HIV infection e.g. HIV encephal
opathy, HIV myelopathy, HIV enteropathy
5.Consequences of chronic immune reactivation e.g. prema
ture CVD death, neurocognitive dysfunction, loss of bone m
ineral density
Siulapwa Rodney 7HIV NOTES 7

8. WHO clinical staging of HIV/AIDS
Primary HIV Infection
•Asymptomatic
•Acute retroviral syndrome (fever, arthralgia, pharyngitis,rash a
nd lymphadenopathy)
Siulapwa Rodney 8
Stage Clinical presentation
1 •Asymptomatic
•Persistent generalised lymphadenopathy
HIV NOTES 8

9. Siulapwa Rodney 9
Clinical Stage Clinical presentation
2 a.Moderate unexplained weight loss (<10%)
b.Recurrent respiratory infections(sinusitis, tonsillitis,
otitis media and pharyngitis)
c.Herpes zoster
d.Angular cheilitis
e.Recurrent oral ulceration
f.Papular pruritic eruptions
g.Seborrhoeic dermatitis
h.Fungal nail infections
3 a.Unexplained severe weight loss( > 10%)
b.Unexplained chronic diarrhoea (> 1 month)
c.Unexplained persistent fever ( > 1month)
d.Persistent oral candidiasis
e.Oral hairly leukoplakia
f.Pulmonary tuberculosis
g.Severe bacterial infections (pneumonia, empyema,
pyomyositis, bone/joint infection, meningitis)
HIV NOTES 9

10. Siulapwa Rodney 10
Clinical Stage Clinical presentation
3 h. Acute necrotising ulcerative stomatitis, gingivitis
i. unexplained anaemia (Hb < 8g/dL)
j. Neutropenia ( < 500cells/µL)
k.Chronic thrombocytopenia ( < 50,000cells/µL)
4 a.HIV wasting syndrome
b.Pneumocystis jiroveci pneumonia
c.Recurrent severe bacterial pneumonia
d.Chronic herpes simplex infection
e.Oesophageal/oropharyngeal candidiasis
f.Extra pulmonary tuberculosis
g.MAC/MAI
h.Progressive multifocal encephalopathy
i.Chronic cryptospridiosis
j.Chronic isosporiasis
k.Disseminated mycosis e.g. histoplasmosis
HIV NOTES 10

11. (WHO, 2007)
Siulapwa Rodney 11
Clinical stage Clinical presentation
4 •Lymphoma
•cervical carcinoma
•HIVAN
•HIV associated cardiomyopathy
HIV NOTES 11

12. Siulapwa Rodney 12HIV NOTES 12

13. Investigations/ Monitoring
Current and previous infections
•Initial diagnosis of HIV infection made by detecting antibo
dies (sero -conversion) against HIV within 3 –4 weeks of i
nfection.
•Up to 3 months of ‘window period’ after exposure require
d to exclude infection.(what does this mean???)
•If HIV infection confirmed, patient should be tested for pot
ential pathogens e.g. syphilis, hepatitis, CMV, varicella zost
er, T. gondii.
CD4 count
•Measures the number of CD4 –positive T –lymphocytes i
n a sample of peripheral blood.
•Normal range is 500 –1500 cells/mm
3
•level of Immunosuppression can be estimated by monitori
ng a patient’s CD4 count.
Siulapwa Rodney 13HIV NOTES 13

14. •CD4 count is used as a major indicator of when to conside
r starting antiretroviral therapy.
Viral load
•Measures the number of HIV RNA in a sample of peripher
al blood.
•Estimates the amountof circulating virus in the blood.
•Correlates with prognosis e.g. high viral load predicts fast
er disease progression.
•Reduction in viral load due to antiretroviral therapy is asso
ciated with clinical benefit.
•Clinical decisions such as when to start or change antiretr
oviral therapies can be made based on viral load.
Resistance testing
•Genotypic HIV resistance test is recommended soon afte
r diagnosis due to potential of transmitted (primary) resistan
ce.
Siulapwa Rodney 14HIV NOTES 14

15. •Resistance testing allows selection of appropriate initial th
erapy.
•Further resistance tests should be performed at any subs
equent virologicalfailure to direct therapy choice.
Tropism testing
•Viruses may enter the cell using CCR5 co-receptor, CXC
R4 co-receptor or both.
•Viruseswhich only use one co-receptor are CCR5 –tropic
or CXCR4 –tropic viruses.
•Viruses which can use both co-receptor types are called d
ual –tropic.
•Mixed –tropic refers to a mixture of virus populations.
•Tests should be performed in real time as viral tropism ch
anges as the disease progresses.
•If CCR5 inhibitors are to be used, it is essential to determin
e that the virus is CCR5 -tropic (no significant use of CXC
R4 receptor)
Siulapwa Rodney 15HIV NOTES 15

16. •If CCR5 inhibitors are to be used, it is essential to determi
ne that the virus is CCR5 -tropic (no significant use of CXC
R4 receptor)
Siulapwa Rodney 16HIV NOTES 16

17. Pharmacological management of HIV Infection
Goals of drug therapy
1.Improve the quality and duration of life
2.Prevent deterioration of immune function and/or restore i
mmune status
3.Treat and/or prevent opportunistic infections
4.Relieve symptoms
Antiretroviral therapy
•Currently one of the fastest evolving areas of medicine.
•Specific details of treatment will continue to change as ne
w drugs emerge.
Siulapwa Rodney 17HIV NOTES 17

18. General principles of antiretroviral therapy
1.A combination of three antiretroviral agents, selected on b
asis of treatment history and resistance tests, should be pr
escribed to increase efficacy and reduce development of dr
ug-resistant virus.
2.A regimen should contain at least one drug that penetrate
s the central nervous system and confers protection agains
t HIV –related encephalopathy/ dementia.
3.Treatment strategies should be adopted that sequence dr
ug combinations, taking potential cross-resistance and futur
e therapy options into consideration.
4.Regimen adopted for a patient should be tailored to suit d
aily lifestyle (high level of adherence is required)
Siulapwa Rodney 18HIV NOTES 18

19. Classes of antiretroviral drugs
1.Nucleosideand nucleotideanalogue reverse transcriptas
e inhibitors( NRTIs)
2.Non –nucleoside reverse transcriptase inhibitors(NNRTIs)
3.Protease inhibitors
4.Entry inhibitors
5.Integrase inhibitors
6.CCR-5 Co-receptor antagonist
Siulapwa Rodney 19HIV NOTES 19

20. Classes of antiretroviral drugs
Siulapwa Rodney 20HIV NOTES 20

21. Nucleoside and nucleotide analogue reverse tran
scriptase inhibitors( NRTIs)
Mechanism of action
•NRTIs are phosphorylatedintracellularly and then inhibit re
verse transcriptase enzyme acting as a false substrate.
•Nucleotideanalogues only require two intracellular phosph
orylations e.g. tenofovir
•Activation of nucleosideanalogues is a three –stage proc
ess.
Siulapwa Rodney 21HIV NOTES 21

22. Examples of NRTIs…..LEADS TZ
•Lamivudine(3TC, Epvir
®
)
•Emtricitabine(FTC, Emtriva
®
)
•Abacavir(ABC, Ziagen
®
)
•Didanosine(ddI, Videx
®
)
•Stavudine(d4T, Zerit
®
)
•Tenofovir(TDF, Viread
®
)
•Zidovudine(AZT, Retrovir
®
)
Combination formulations
1.Abacavir + lamivudine (Kivexa
®
)
2.Tenofovir + emtricitabine (Truvuda
®
)
3.Zidovudine + lamivudine ( combivir
®
)
4.Zidovudine + lamivudine + abacavir ( Trizivir
®
)
Siulapwa Rodney 22HIV NOTES 22

23. Formulation combining two NRTIs with an NNRTI:
•Tenofovir + emtricitabine + efavirenz ( Atripla
®
)
Combinations that should be avoided:
•Zidovudine + stavudine ( intracellular competition resulting
in antagonism)
•Stavudine + didanosine (unacceptable toxicity i.e. lactic aci
dosis, lipodystrophy)
•Tenofovir + didanosine (unacceptable rates of virological fa
ilure and potential CD4 count decline)
Adverse effects of NRTIs
•ABC–Usually well tolerated
•Rash, headache, nausea and vomiting,diarrhoea, reduced
appetite (common side effects)
•Lactic acidosis, may increase risk of cardiovascular diseas
e.
Siulapwa Rodney 23HIV NOTES 23

24. •ddI–nausea, bloating, diarrhoea
•Pancreatitis, liver failure, peripheral neuropathy, hyperuricaemi
a, lactic acidosis
•FTC–Headache(most common), nausea, diarrhoea, dizzines
s, lactic acidosis
•3TC–Generally well tolerated
•GI disturbances, headache, anaemia, neutropenia
•Lactic acidosis
•d4T–peripheral neuropathy, pancreatitis, lactic acidosis, incre
ased risk of lipoatrophy/lipodystrophysyndrome.
•TDF–diarrhoea, nausea and vomiting, flatulence and headac
he (most common)
•Renal impairment and hypophosphataemia.
•AZT–nausea, vomiting, headache, fatigue, muscle pain
(common)
Siulapwa Rodney 24HIV NOTES 24

25. •AZT–haematological toxicities (neutropenia, anaemia), myop
athy, lactic acidosis, increased risk of lipoatrophy/lipodystrophy
syndrome.
Non -nucleoside analogue reverse transcriptase inhibitor
s( NNRTIs)
Mechanism of action
•NNRTIs inhibit the reverse transcriptase enzyme by binding to
its active site.
•They do not require prior phosphorylation and can act on cell –
free virions as well as infected cells.
Siulapwa Rodney 25HIV NOTES 25

26. Examples of NNRTIs
•Efavirenz(EFV, Sustiva
®
)
•Nevirapine(NVP, Viramune
®
)
•Etravirine(ETR, Intelence
®
)
•Rilpivirine(RPV, Edurant
®
)
•Resistance to NNRTIs occurs rapidlyin incompletely suppressiv
e regimens and it is therefore essential that they are prescribed
with at least two NRTIs or a combination of NRTIs and PIs.
•Cross resistance between NVP and EFV is high.
•Etravirine has a different resistance profile( used as an alternati
ve first –line NNRTI)
•NNRTIs have much longer plasma half –lives than PIs and NR
TIs
Siulapwa Rodney 26HIV NOTES 26

27. •When stopping NNRTI-based regimens, continue other agents
for a period after cessation of NNRTI or switching to a boosted
PI prior to regimen discontinuation. ..this is what we call coverin
g the tail or tail cover of NNRTIs.7 days cover
Adverse effects of NNRTIs
•EFV–CNS disturbances (sedation, feeling stoned, dizzy, impai
red concentration, vivid dreams, mood swings, hallucinations)
•Rash
•Raised LFTs
•Hyperlipidaemia
•lactic acidosis, may increase risk of cardiovascular disease
•NVP–Rash, raised LFTs/hepatitis,
•Nausea, headache, sedation, fatigue
•Should not be started in women with CD4 count > 250cells/mm
3
or men with CD4 count > 400cells/mm
3
: greater risk of rash –
associated hepatic events.
Siulapwa Rodney 27HIV NOTES 27

28. •ETV–Rash,
•nausea,
•Diarrhoea, abdominal pain
•Headache, pyrexia, fatigue
•RPV–Headache, depression, insomnia, rash, raised LFT
s, lipodystrophy
•Less CNS disturbances than efavirenz and non –teratoge
nic.
Protease inhibitors (PIs)
Mechanism of action
•PIs bind to the active site of the HIV –1 protease enz
yme, preventing the maturation of newly produced virions
so that they remain non –infectious
Siulapwa Rodney 28HIV NOTES 28

29. Examples of PIs
•Atazanavir(ATV, Reyataz
®
)
•Darunavir (DRV, Prezista
®
)
•Fosamprenavir (FPV, Telzir
®
)
•Indinavir(IDV, Crixavan
®
)
•Lopinavirco –formulated with ritonavir (LPV/r, Kaletra
®
)
(ritonavir does not add to antiviral activity -it is a pharmacokineti
c enhancer)
•Nelfinavir(NFV, Viracept
®
)
•Ritonavir(RTV, Norvir
®
)
•Saquinavir(SQV, Invirase
®
)
•Tipranavir (TPV, Aptivus
®
)
•RAINS LTDF
Siulapwa Rodney 29HIV NOTES 29

30. •Use of ritonavir –boosted PIs has superseded use of single
PIs due to:
1.Better pharmacokinetic profiles( ↑ C
max, ↑ t
1/2due to inhibitio
n of cytochrome P450 enzymes)
2.Superior efficacy data
3.Reduced likelihood of resistance development
•Newer PIs such as TPV and DRV are effective against ma
ny viruses resistant to earlier PIs.
•DRVis used in first –line PI therapy as once daily boosted a
gent (800mg with 100mg of ritonavir).
•Cobicistatis an alternative booster to ritonavir e.g.
Siulapwa Rodney 30HIV NOTES 30

31. Adverse effects of PIs
•ATV–Nausea, diarrhoea, headache, rash, jaundice (most co
mmon)
•Hperbilirubinaemia
•Raised LFTs
•Does not appear to elevate lipids
•ECG changes
•lipodystrophy
•DRV–Nausea, vomiting, diarrhoea, constipation, abdominal
pain, rash Hyperlipidaemia(most common)
•raised LFTs
•Lipodystrophy
•FPV-Nausea, vomiting, diarrhoea, rash, fatigue (most com
mon)
•Hyperlipidaemia,raised LFTs, Lipodystrophy
Siulapwa Rodney 31HIV NOTES 31

32. •NFV–diarrhoea and flatulence, nausea,(most common)
•Hyperglycaemia
•Lipodystrophy
•SQV-Nausea, vomiting, diarrhoea, abdominal pain, anorexia,
asthenia
•Prolonged QT interval,raised LFTs, Lipodystrophy
•TPV-Nausea, vomiting, diarrhoea, fatigue,raised LFTs, Lipo
dystrophy
Entry inhibitors
•currently two types of entry inhibitors (fusion inhibitors and C
CR5 inhibitors) are available.
.
Siulapwa Rodney 32HIV NOTES 32

33. Fusion inhibitors
Mechanism of action
•Block the structural rearrangement of HIV –1 gp41 thus stop t
he fusion of the viral cell membrane with the target cell membr
ane, preventing viral RNA from entering the cell.
•Enfuvirtide(T –20, Fuzeon
®
)is administered subcutaneously
and largely used in heavily treatment experienced patients.
•Main side effect is injection site reaction.
Adverse effects
•Insomnia,
•headache,
•lymphadenopathy,
•eosinophilia
•hypersensitivity reactions
Siulapwa Rodney 33HIV NOTES 33

34. CCR5 inhibitors
Mechanism of action
•Selectively bind to the human chemokine receptor CCR5, pre
venting CCR5 –tropic HIV –1 from entering cells.
•Maraviroc (MVC, Celsentri
®
) is indicated for use in patients wit
h only CCR5 –tropic virus, which is determined by tropism just
prior to commencing treatment.
•Usually used in patients with resistance to one or more other
antiretroviral classes.
Adverse effects
•Nausea (most common)
•Vomiting, abdominal pain, constipation, bloating
•Dizziness, paraesthesia, somnolence, rash, insomnia, raised
LFTs
Siulapwa Rodney 34HIV NOTES 34

35. Integrase inhibitors
Mechanism of action
•Bind to integrase enzyme, thus blocking the integration of viral
DNA into host DNA.
•Was initially used in patients with resistant virus
•Increasingly used in first –line regimens or where tolerability
with initial regimens is an issue.
Examples include:
•Raltegravir(RAL, Isentress
®
)
•Elvitegravir(requires boosting with cobicistat)
•Dolutegravir
Adverse effects
•Nausea and headache, dizziness, vertigo, abdominal pain, flat
ulence, constipation, pruritus, arthralgia, fatigue, raised creatin
e kinase, myopathy and rhabdomyolysis.
Siulapwa Rodney 35HIV NOTES 35

36. Toxicity of antiretroviral therapies
Mitochondrial toxicity
•Increasingly recognised in patients with prolonged exposur
e to nucleoside analogue antiretrovirals e.g. d4T, ddI and to
a lesser extent, AZT.
•Explains such side effects as peripheral neuropathy, myop
athy, pancreatitis, and lactic acidosis.
•Side effects are managed by switching the likely offending
agent, if possible.
•NRTIs also function as substrates for other enzymes like D
NA polymerase gamma(involved in the replication of mitoc
hondrial DNA)
•Disruption of DNA polymerase gamma is thought to result i
n a wide variety of adverse effects ranging from lactic
acidosis to hepatic steatosis
Siulapwa Rodney 36HIV NOTES 36

37. Rash and hepatitis
•recognised as common side effects of NNRTIs.
•Incidence and severity appear greatest with NVP in patients w
ith higher CD4 count (>250cells/mm
3
for women and > 400cell
s/mm
3
for men)
•Management is either close observation (mild-to-moderate ca
ses) or withdrawal of offending drug(severe cases).
•ABC Hypersensitivity presents in the first 6 weeks of therapy a
s a progressive illness with fevers, rash and flu-like symptoms.
•Manage ABC –induced hypersensitivity by withdrawing ABC.
Siulapwa Rodney 37HIV NOTES 37

38. Lipodystrophy
•Characterised by lipoatrophy ( fat loss from the face , upper li
mbs and buttocks) and/ or lipohypertrophy (abnormal fat depos
ition, affecting the abdomen and neck).
•d4T and AZT are associated with lipoatrophy while PIs induce
lipohypertrophy.
•Managementinvolvesavoidingorswitchingawayfromoffendi
ngdrugsand/orcosmeticapproaches(fillersorliposuction).
Metabolic disturbances
•Hypercholesterolaemia and hypertriglyceridaemia are associa
ted with PIs.
•Incidence appears lower with ATV.
•Managed by reducing modifiable risk factors, switch away fro
m offending agent to a metabolically favourable agent or adjun
ctive lipid -lowering therapy
Siulapwa Rodney 38HIV NOTES 38

39. • Renal impairment
Renal impairmenthas been reported with TDF.
•Creatinine clearance should be calculated and proteinuriaqu
antified prior to commencing therapy with TDF and should be
monitored regularly.
Cardiovascular disease
•Increased risk of cardiovascular disease is associated with us
e of some PIs ( LPV/r, IDV) and with NRTI, ABC.
•Risk is independent of the effects on lipids and mechanism is
yet to be determined.
Siulapwa Rodney 39HIV NOTES 39

40. Preferred 1st line cART and alternative regimens by specific
populations
•XTC is3TC orFTC
•EFV is the preferred NNRTI for first line cART initiation.
•Consider using EFV at all times unless there are contraindications to it
s use.
•EFV is associated with central nervous system(CNS) side effects (e.g. d
izziness, drowsiness, insomnia, abnormal dreams, and impaired concen
tration) that generally occur with the first few doses and usually diminis
h or disappear after 2-4 weeks.
Special popul
ations
Description Preferred 1st line cA
RT
Alternative regimen
Adults A once-daily fixe
d-dose combinat
ion
is recommended
TDF (TAF) + XTC +DT
G
TDF (TAF) + XTC + EFV
ABC +3TC + DTG
40HIV NOTES 40

41. Pregnancy/breastfeeding
Special populati
ons
Description Preferred 1st line cA
RT
Alternative regime
n
Pregnant & Bre
astfeeding
Women
A once-daily fixe
d-dose combinat
ion
is recommended
TDF + XTC + DTG TDF + XTC + EFV
or
ABC + 3TC + DTG
41HIV NOTES 41

42. Children (0 -2weeks)
•First-line regimen: AZT + 3TC + NVP
•Alternative regimen: AZT + 3TC + RAL
Children (2 weeks -5 years old)
•Less than 20kg
•First-line regimen: ABC + 3TC +LPVr
•Alternative regimen: AZT +3TC+LPVr or AZT +3TC + RAL
42HIV NOTES 42

43. Children (2 weeks -5 years old)
•BETWEEN 20 -24.9KG
•First-line regimen: ABC + 3TC + DTG
•Alternative regimen: AZT +3TC+LPVr or ABC +3TC + LPVr
•Equal or greater than 25KG
•First-line regimen: TAF+ XTC + DTG
43HIV NOTES 43

44. Elimination of Mother to child Transmi
ssion (EMTCT)
•CHILD BORN TO HIV POSTIVE MOTHER.
1.AT BIRTH
Do HIV testing, if negative start :
AZT + 3TC +NVP for 12 weeks
2. AFTER 6 WEEKS
Test still negative , continue with AZT + 3TC +N
VP
3. AFTER 10 WEEKS
Test still negative , continue with AZT + 3TC +NV
P
44HIV NOTES 44

45. Elimination of Mother to child Transmi
ssion (EMTCT)
4. AFTER 14 WEEKS
Test still negative , continue with AZT + 3TC +N
VP
If mother virally suppressed stop AZT + 3TC +N
VP
5. AFTER 6 MONTHS
Test still negative , continue with AZT + 3TC +NV
P
If mother virally suppressed stop AZT + 3TC +NVP
45HIV NOTES 45

46. FIRST LINE FOR HIV 2/ HIV 1 CO IN
FECTION
•1. ADULTS
TDF (TAF) +3TC + DTG
•2. CHILDREN
ABC + 3TC + LPVr
46HIV NOTES 46

47. SECOND LINE TREATMENT
1 . CHILDREN > 5 YEARS
FIRST LINE: ABC + 3TC + LPVr
SECOND LINE : AZT + 3TC + RAL or AZT + 3TC
+ DTG
2 CHILDREN 5 -10 YEARS
FIRST LINE: ABC + 3TC + EFV
SECOND LINE : AZT + 3TC + LPV r or AZT + 3T
C + DTG
3.ADULTS
FIRST LINE: TDF + 3TC + DTG
SECOND LINE : AZT + 3TC + LPVr
FIRST LINE: TDF + XTC + EFV
47HIV NOTES 47

48. PRE EXPOSURE PROPHYLAXIS (P
rEP)
•The recommended treatment :
TDF or TAF + XTC
PrEP only becomes effective after 7days (21 day i
n women) after starting the medications
PrEP should be discontinued after 4 weeks of eli
mination of risky exposure
48HIV NOTES 48

49. Post Exposure Prophylaxis
•Recommended treatment
1. medium risk: invasive injury, no blood visible on
the needle
Preferred treatment: TDF or TAF + XTC +DTG
Alternative treatment : TDF or TAF + XTC + DRVr
•2. high risk: large volume of blood/fluids, known
HIV patient, large bore needle, deep extensive inj
ury
Preferred treatment: TDF or TAF + XTC + LPVr
Alternative treatment : TDF or TAF + XTC + ATVr
49HIV NOTES 49

50. Post Exposure Prophylaxis
3. penetrative sexual abuse
•AZT + 3TC + LPVr (children < 20kg)
•AZT + 3TC + DTG (children equal or greater than
20kg)
•TAF + FTC + DTG (children equal or greater than
25kg)
50HIV NOTES 50